AGN-190584
ApprovedWithdrawn 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Presbyopia
Conditions
Presbyopia
Trial Timeline
Dec 1, 2022 → Jun 30, 2023
NCT ID
NCT05624320About AGN-190584
AGN-190584 is a approved stage product being developed by AbbVie for Presbyopia. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05624320. Target conditions include Presbyopia.
What happened to similar drugs?
0 of 5 similar drugs in Presbyopia were approved
Approved (0) Terminated (0) Active (5)
🔄Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + Placebo (Vehicle) ophthalmic solutionLENZ TherapeuticsPhase 3
🔄Aceclidine+Brimonidine combination ophthalmic solution + Placebo + Aceclidine Ophthalmic SolutionLENZ TherapeuticsPhase 3
🔄Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + VehicleLENZ TherapeuticsPhase 3
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05624320 | Approved | Withdrawn |
Competing Products
14 competing products in Presbyopia